Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Ginekologia Polska
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2023

open access

Vol 92, No 2 (2021)
Review paper
Published online: 2020-10-20
View PDF Download PDF file
Get Citation

Peripartum cardiomyopathy — a cardiovascular disease in pregnancy and puerperium. The actual state of knowledge, challenges, and perspectives

Karolina E. Kryczka1, Marcin Demkow1, Zofia Dzielinska1
DOI: 10.5603/GP.a2020.0171
·
Pubmed: 33084016
·
Ginekol Pol 2021;92(2):147-152.
Affiliations
  1. Department of Coronary and Structural Heart Diseases, National Institute of Cardiology, Warsaw, Poland

open access

Vol 92, No 2 (2021)
REVIEW PAPERS Obstetrics
Published online: 2020-10-20

Abstract

Peripartum cardiomyopathy (PPCM) is an idiopathic, multifactor cause of heart failure occurring at the end of pregnancy
or in the first months after delivery. Although the prevalence of the disease is increasing, the awareness of both physicians
and patients is rather low. Symptoms of PPCM are unspecific, making a prompt diagnosis even more difficult. In severe
functional insufficiency and dilatation of the left ventricle, the recovery rate is particularly low. Therefore, the later PPCM
is diagnosed, the more severe heart failure, and the worse the patient’s outcome.
Despite the increasing frequency of PPCM, the exact pathophysiology and predictors of outcome are still not well determined.
Therapeutic management in patients with PPCM remains a challenge, requiring a multidisciplinary approach.
At the base of the disease lies dysfunction of microcirculation with 16-kDa prolactin as the main trigger of this state. Therefore,
adding bromocriptine to standard heart failure pharmacotherapy may be particularly beneficial.
In this review, we present the current state of knowledge and diagnostic and management recommendations and perspectives.

Abstract

Peripartum cardiomyopathy (PPCM) is an idiopathic, multifactor cause of heart failure occurring at the end of pregnancy
or in the first months after delivery. Although the prevalence of the disease is increasing, the awareness of both physicians
and patients is rather low. Symptoms of PPCM are unspecific, making a prompt diagnosis even more difficult. In severe
functional insufficiency and dilatation of the left ventricle, the recovery rate is particularly low. Therefore, the later PPCM
is diagnosed, the more severe heart failure, and the worse the patient’s outcome.
Despite the increasing frequency of PPCM, the exact pathophysiology and predictors of outcome are still not well determined.
Therapeutic management in patients with PPCM remains a challenge, requiring a multidisciplinary approach.
At the base of the disease lies dysfunction of microcirculation with 16-kDa prolactin as the main trigger of this state. Therefore,
adding bromocriptine to standard heart failure pharmacotherapy may be particularly beneficial.
In this review, we present the current state of knowledge and diagnostic and management recommendations and perspectives.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

peripartum cardiomyopathy; pregnancy; bromocriptine

About this article
Title

Peripartum cardiomyopathy — a cardiovascular disease in pregnancy and puerperium. The actual state of knowledge, challenges, and perspectives

Journal

Ginekologia Polska

Issue

Vol 92, No 2 (2021)

Article type

Review paper

Pages

147-152

Published online

2020-10-20

Page views

1097

Article views/downloads

1164

DOI

10.5603/GP.a2020.0171

Pubmed

33084016

Bibliographic record

Ginekol Pol 2021;92(2):147-152.

Keywords

peripartum cardiomyopathy
pregnancy
bromocriptine

Authors

Karolina E. Kryczka
Marcin Demkow
Zofia Dzielinska

References (35)
  1. Roos-Hesselink JW, Duvekot JJ, Thorne SA. Pregnancy in high risk cardiac conditions. Heart. 2009; 95(8): 680–686.
    CrossRefPubMed
  2. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010; 12(8): 767–778.
    CrossRefPubMed
  3. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007; 128(3): 589–600.
    CrossRefPubMed
  4. Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation. 2010; 121(13): 1465–1473.
    CrossRefPubMed
  5. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2016; 18(9): 1096–1105.
    CrossRefPubMed
  6. Haghikia A, Podewski E, Libhaber E, et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol. 2013; 108(4): 366.
    CrossRefPubMed
  7. Kamiya CA, Kitakaze M, Ishibashi-Ueda H, et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. -Results from the Japanese Nationwide survey of peripartum cardiomyopathy-. Circ J. 2011; 75(8): 1975–1981.
    CrossRefPubMed
  8. Kryczka K, Dzielińska Z, Przybylski A, et al. Therapeutic challenges and management of heart failure during pregnancy (part I). Med Sci Monit. 2012; 18(5): CQ5–CQ7.
    CrossRefPubMed
  9. Hilfiker-Kleiner D, Haghikia A, Nonhoff J, et al. Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J. 2015; 36(18): 1090–1097.
    CrossRefPubMed
  10. Mielniczuk LM, Williams K, Davis DR, et al. Frequency of peripartum cardiomyopathy. Am J Cardiol. 2006; 97(12): 1765–1768.
    CrossRefPubMed
  11. Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol. 2011; 58(7): 659–670.
    CrossRefPubMed
  12. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur J Heart Fail. 2017; 19(9): 1131–1141.
    CrossRefPubMed
  13. Sliwa K, Bauersachs J. EURObservational Research Programme Peripartum Cardiomyopathy (PPCM) Registry 26 May 2018 HFA 2018, Vienna.
  14. Fett JD, Markham DW. Discoveries in peripartum cardiomyopathy. Trends Cardiovasc Med. 2015; 25(5): 401–406.
    CrossRefPubMed
  15. Sliwa K, Förster O, Libhaber E, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006; 27(4): 441–446.
    CrossRefPubMed
  16. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018; 39(34): 3165–3241.
    CrossRefPubMed
  17. Forster O, Hilfiker-Kleiner D, Ansari AA, et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2008; 10(9): 861–868.
    CrossRefPubMed
  18. Fidziańska A, Walczak E, Glinka Z, et al. Ultrastructural evidence of myocardial capillary remodeling in peripartum cardiomyopathy. Med Sci Monit. 2010; 16 (5): CS62-66. https://www.medscimonit.com/download/index/idArt/878530.
  19. Mebazaa A, Seronde MF, Gayat E, et al. Imbalanced Angiogenesis in Peripartum Cardiomyopathy　- Diagnostic Value of Placenta Growth Factor. Circ J. 2017; 81(11): 1654–1661.
    CrossRefPubMed
  20. Halkein J, Tabruyn SP, Ricke-Hoch M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest. 2013; 123(5): 2143–2154.
    CrossRefPubMed
  21. van Spaendonck-Zwarts KY, Posafalvi A, van den Berg MP, et al. Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. Eur Heart J. 2014; 35(32): 2165–2173.
    CrossRefPubMed
  22. Kryczka KE, Dzielińska Z, Franaszczyk M, et al. Severe Course of Peripartum Cardiomyopathy and Subsequent Recovery in a Patient with a Novel TTN Gene-Truncating Mutation. Am J Case Rep. 2018; 19: 820–824.
    CrossRefPubMed
  23. McNamara DM, Elkayam U, Alharethi R, et al. IPAC Investigators. Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015; 66(8): 905–914.
    CrossRefPubMed
  24. Liang YD, Xu YW, Li WH, et al. Left ventricular function recovery in peripartum cardiomyopathy: a cardiovascular magnetic resonance study by myocardial T1 and T2 mapping. J Cardiovasc Magn Reson. 2020; 22(1): 2.
    CrossRefPubMed
  25. Azibani F, Pfeffer TJ, Ricke-Hoch M, et al. Outcome in German and South African peripartum cardiomyopathy cohorts associates with medical therapy and fibrosis markers. ESC Heart Fail. 2020; 7(2): 512–522.
    CrossRefPubMed
  26. Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–2200.
    CrossRefPubMed
  27. Azibani F, Sliwa K. Peripartum Cardiomyopathy: an Update. Curr Heart Fail Rep. 2018; 15(5): 297–306.
    CrossRefPubMed
  28. Arrigo M, Blet A, Mebazaa A. Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD. Eur Heart J. 2017; 38(35): 2680–2682.
    CrossRefPubMed
  29. Hilfiker-Kleiner D, Haghikia A, Berliner D, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J. 2017; 38(35): 2671–2679.
    CrossRefPubMed
  30. https://clinicaltrials.gov/ct2/show/study/NCT02590601.
  31. Ricke-Hoch M, Hoes MF, Pfeffer TJ, et al. In peripartum cardiomyopathy plasminogen activator inhibitor-1 is a potential new biomarker with controversial roles. Cardiovasc Res. 2020; 116(11): 1875–1886.
    CrossRefPubMed
  32. Rasmusson K, Brunisholz K, Budge D, et al. Peripartum cardiomyopathy: post-transplant outcomes from the United Network for Organ Sharing Database. J Heart Lung Transplant. 2012; 31(2): 180–186.
    CrossRefPubMed
  33. Biteker M, Ilhan E, Biteker G, et al. Delayed recovery in peripartum cardiomyopathy: an indication for long-term follow-up and sustained therapy. Eur J Heart Fail. 2012; 14(8): 895–901.
    CrossRefPubMed
  34. Hilfiker-Kleiner D, Haghikia A, Masuko D, et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol. 2013; 108(4): 366–1728.
    CrossRefPubMed
  35. Groer M, Jevitt C. Symptoms and signs associated with postpartum thyroiditis. J Thyroid Res. 2014; 2014: 531969.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl